Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
Hematological manifestations and complications of Gaucher disease
Revel-Vilk, S; Szer, J; Zimran, A
(2021), Expert Rev. Hematol., 347-354
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib
Tam, CS; Ou, YC; Trotman, J; Opat, S
(2021), Expert Rev. Clin. Pharmacol., 1329-1344
Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring
Ho, SA; Slavin, M; Roberts, JA; Yong, M
(2021), Expert Rev. Anti-Infect. Ther., 707-718
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
Boyle, S; Wellard, C; Moore, EM; Blacklock, H; Harrison, SJ; Ho, PJ; Hocking, J; McQuilten, ZK; Quach, H; Spearing, R; Wood, EM; Spencer, A; Mollee, P
(2021), Eur. J. Haematol., 497-499
DOI: 10.1111/ejh.13677
Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15
MacManus, MP; Roos, D; O'Brien, P; Capp, A; Wirth, A; Tsang, R; Bressel, M; Lade, S; Seymour, JF
(2021), Eur. J. Cancer, 129-138
Transient, flexible gene editing in zebrafish neutrophils and macrophages for determination of cell-autonomous functions
Isiaku, AI; Zhang, ZB; Pazhakh, V; Manley, HR; Thompson, ER; Fox, LC; Yerneni, S; Blombery, P; Lieschke, GJ
(2021), Dis. Model. Mech.
DOI: 10.1242/dmm.047431
Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy
Campbell, BA; Lasocki, A; Oon, SF; Bressel, M; Goroncy, N; Dwyer, M; Wiltshire, K; Seymour, JF; Mason, K; Tange, D; Xu, M; Wheeler, G
(2021), Clin. Oncol., E425-E432
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)
Bergin, K; Wellard, C; Moore, E; McQuilten, Z; Blacklock, H; Harrison, SJ; Ho, PJ; King, T; Quach, H; Mollee, P; Walker, P; Wood, E; Spencer, A
(2021), Clin. Lymphoma Myeloma Leuk., E510-E520
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies
Lim, C; Sinha, P; Harrison, SJ; Quach, H; Slavin, MA; Teh, BW
(2021), Clin. Lymphoma Myeloma Leuk., 444
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Punnoose, E; Peale, FV; Szafer-Glusman, E; Lei, GY; Bourgon, R; Do, AD; Kim, E; Zhang, LP; Farinha, P; Gascoyne, RD; Munoz, FJ; Martelli, M; Mottok, A; Salles, GA; Sehn, LH; Seymour, JF; Trneny, M; Oestergaard, MZ; Mundt, KE; Vitolo, U
(2021), Clin. Lymphoma Myeloma Leuk., 267
Advances in Frontline Management of Peripheral T-cell Lymphoma
Abeyakoon, C; van der Weyden, C; Harrop, S; Khot, A; Dickinson, M; Yannakou, CK; Prince, HM
(2021), Clin. Lymphoma Myeloma Leuk., 368-378
Re-examining ferritin-bound iron: current and developing clinical tools
Grant, ES; Clucas, DB; McColl, G; Hall, LT; Simpson, DA
(2021), Clin. Chem. Lab. Med., 459-471
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Davids, MS; Roberts, AW; Kenkre, VP; Wierda, WG; Kumar, A; Kipps, TJ; Boyer, M; Salem, AH; Pesko, JC; Arzt, JA; Mantas, M; Kim, SY; Seymour, JF
(2021), Clin. Cancer Res., 4690-4695
Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma
Doerflinger, M; Garnham, AL; Freytag, S; Harrison, SJ; Prince, HM; Quach, H; Slavin, MA; Pellegrini, M; Teh, BW
(2021), Clin. Transl. Immunol.
DOI: 10.1002/cti2.1235
Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy
Shanavas, M; Law, SC; Hertzberg, M; Hicks, RJ; Seymour, JF; Li, ZX; de Long, LM; Nath, K; Sabdia, MB; Gunawardana, J; Gandhi, MK; Keane, C
(2021), Clin. Transl. Immunol.
DOI: 10.1002/cti2.1351
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
Beaumont, S; Harrison, S; Er, J
(2021), Cancers
Venetoclax and navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Pullarkat, VA; Lacayo, NJ; Jabbour, E; Rubnitz, JE; Bajel, A; Laetsch, TW; Leonard, J; Colace, SI; Khaw, SL; Fleming, SA; Mattison, RJ; Norris, R; Opferman, JT; Roberts, KG; Zhao, YQ; Qu, CX; Badawi, M; Schmidt, M; Tong, B; Pesko, JC; Sun, Y; Ross, JA; Vishwamitra, D; Rosenwinkel, L; Kim, SY; Jacobson, A; Mullighan, CG; Alexander, TB; Stock, W
(2021), Cancer Discov., 1440-1453
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Harrison, SJ; Perrot, A; Alegre, A; Simpson, D; Wang, MC; Spencer, A; Delimpasi, S; Hulin, C; Sunami, K; Facon, T; Vlummens, P; Yong, K; Campana, F; Inchauspe, M; Mace, S; Risse, ML; Velde, H; Richardson, P
(2021), Br. J. Haematol., 120-131
DOI: 10.1111/bjh.17499
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target
Gould, C; Lickiss, J; Kankanige, Y; Yemeni, S; Lade, S; Gandhi, MK; Chin, C; Yannakou, CK; Villa, D; Slack, GW; Markham, JF; Tam, CS; Nelson, N; Seymour, JF; Dickinson, M; Neeson, PJ; Westerman, D; Blombery, P
(2021), Br. J. Haematol., 113-118
DOI: 10.1111/bjh.17789
T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection
Kuzich, JA; Kankanige, Y; Guinto, J; Ryland, G; McBean, M; Wong, E; Koldej, R; Collins, J; Westerman, D; Ritchie, D; Blombery, P
(2021), Bone Marrow Transplant., 2582-2590
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Bergin, K; Wellard, C; Augustson, B; Cooke, R; Blacklock, H; Harrison, SJ; Ho, J; King, T; Quach, H; Mollee, P; Walker, P; Moore, E; McQuilten, Z; Wood, E; Spencer, A
(2021), Bone Marrow Transplant., 2533-2543
Protocol for a multicentre, parallel-group, open-label randomised controlled trial comparing ferric carboxymaltose with the standard of care in anaemic Malawian pregnant women: the REVAMP trial
Mwangi, MN; Mzembe, G; Moya, E; Braat, S; Harding, R; Robberstad, B; Simpson, J; Stones, W; Rogerson, S; Biselele, K; Chinkhumba, J; Larson, L; Ataide, R; Phiri, KS; Pasricha, SR
(2021), BMJ Open
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap
Longhitano, AP; Slavin, MA; Harrison, SJ; Teh, BW
(2021), Blood Rev.
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Tam, CS; Opat, S; Simpson, D; Cull, G; Munoz, J; Phillips, TJ; Kim, WS; Rule, S; Atwal, SK; Wei, R; Novotny, W; Huang, J; Wang, M; Trotman, J
(2021), Blood Adv., 2577-2585
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
Mueller, KT; Grupp, SA; Maude, SL; Levine, JE; Pulsipher, MA; Boyer, MW; August, KJ; Myers, GD; Tam, CS; Jaeger, U; Foley, SR; Borchmann, P; Schuster, SJ; Waller, EK; Awasthi, R; Potthoff, B; Warren, A; Waldron, ER; McBlane, F; Chassot-Agostinho, A; Laetsch, TW
(2021), Blood Adv., 4980-4991
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
Dickinson, M; Briones, J; Herrera, AF; Gonzalez-Barca, E; Ghosh, N; Cordoba, R; Rutherford, SC; Bournazou, E; Labriola-Tompkins, E; Franjkovic, I; Chesne, E; Brouwer-Visser, J; Lechner, K; Brennan, B; Nuesch, E; DeMario, M; Ruttinger, D; Kornacker, M; Hutchings, M
(2021), Blood Adv., 4762-4770
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
Lew, TE; Lin, VS; Cliff, ER; Blombery, P; Thompson, ER; Handunnetti, SM; Westerman, DA; Kuss, BJ; Tam, CS; Huang, DCS; Seymour, JF; Roberts, AW; Anderson, MA
(2021), Blood Adv., 4054-4058
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Tiong, IS; Dillon, R; Ivey, A; Kuzich, JA; Thiagarajah, N; Sharplin, KM; Kok, CH; Tedjaseputra, A; Rowland, JP; Grove, CS; Abro, E; Shortt, J; Hiwase, DK; Bajel, A; Potter, NE; Smith, ML; Hemmaway, CJ; Thomas, A; Gilkes, AF; Russell, NH; Wei, AH
(2021), Blood Adv., 5107-5111
KRd: the new KiD in the French myeloma induction class
Er, J; Harrison, SJ
(2021), Blood, 105-106
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells
Micklethwaite, KP; Gowrishankar, K; Gloss, BS; Li, ZD; Street, JA; Moezzi, L; Mach, MA; Sutrave, G; Clancy, LE; Bishop, DC; Louie, RHY; Cai, C; Foox, J; MacKay, M; Sedlazeck, FJ; Blombery, P; Mason, CE; Luciani, F; Gottlieb, DJ; Blyth, E
(2021), Blood, 1391-1405